HIDALGO, Manuel, Frederic AMANT, Andrew V. BIANKIN, Eva BUDINSKÁ, Annete T. BYRNE, Carlos CALDAS, Robert B. CLARKE, Steven de JONG, Jos JONKERS, Gundhild Mari MAELANDSMO, Sergio ROMAN-ROMAN, Joan SEOANE, Livio TRUSOLINO and Alberto VILLANUEVA. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery. Philadelphia: American Association for Cancer Research Inc., 2014, vol. 4, No 9, p. 998-1013. ISSN 2159-8274. Available from: https://dx.doi.org/10.1158/2159-8290.CD-14-0001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Authors HIDALGO, Manuel (724 Spain), Frederic AMANT (56 Belgium), Andrew V. BIANKIN (826 United Kingdom of Great Britain and Northern Ireland), Eva BUDINSKÁ (703 Slovakia, guarantor, belonging to the institution), Annete T. BYRNE (372 Ireland), Carlos CALDAS (826 United Kingdom of Great Britain and Northern Ireland), Robert B. CLARKE (826 United Kingdom of Great Britain and Northern Ireland), Steven de JONG (528 Netherlands), Jos JONKERS (528 Netherlands), Gundhild Mari MAELANDSMO (578 Norway), Sergio ROMAN-ROMAN (250 France), Joan SEOANE (724 Spain), Livio TRUSOLINO (380 Italy) and Alberto VILLANUEVA (724 Spain).
Edition Cancer Discovery, Philadelphia, American Association for Cancer Research Inc. 2014, 2159-8274.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 19.453
RIV identification code RIV/00216224:14110/14:00078130
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1158/2159-8290.CD-14-0001
UT WoS 000343121400023
Keywords in English HUMAN PANCREATIC-CANCER; TUMOR XENOGRAFTS; NUDE-MICE; COLORECTAL-CANCER; STEM-CELLS; IN-VIVO; PERSONALIZED CHEMOTHERAPY; THERAPEUTIC RESPONSE; IMMUNODEFICIENT MICE; DRUG DEVELOPMENT
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 9/1/2015 14:10.
Abstract
Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.
PrintDisplayed: 21/7/2024 00:33